Also known as: shingles
The European Medicines Agency is enforcing clinical trial transparency and has launched a new vaccine information initiative, while a coalition of health professionals warns of suboptimal vaccination coverage across Europe. An analysis also shows that only a portion of EMA-approved medicines are available to NHS patients in England after additional assessments.
The FDA pulled back publication of several studies on COVID-19 and shingles vaccines. The blocked studies involved millions of patient records, and two COVID-19 papers were withdrawn in October 2025.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06207487 |
Clinical and Economic Impact of Herpes Zoster in Cancer Patients |
COMPLETED | |
| NCT05701800 |
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age |
TERMINATED | PHASE1 |
| NCT05580458 |
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population |
RECRUITING | PHASE1/PHASE2 |
